A large community study in Hubei, China, suggests a menstrual-pad blood sample can detect human papillomavirus (HPV) and identify cervical precancer with accuracy comparable to clinician-collected samples. Between 2021 and 2025, 3,068 women aged 20 to 54 with regular cycles provided menstrual-pad strips, clinician-collected cervical samples, and an additional lab sample for comparison. The pad-derived samples showed 94.7% sensitivity for detecting CIN2, versus 92.1% for clinician-collected material, and negative predictive values and referral rates were similar across methods. Authors published the results in BMJ and described the approach as a standardised, non-invasive alternative that could expand screening options.
Key Takeaways
- The study enrolled 3,068 women in Hubei, China, from 2021 to 2025 and compared three paired samples per participant: menstrual-pad blood, clinician-collected cervical swab, and a laboratory-processed extra sample.
- Menstrual-pad samples detected CIN2 with 94.7% sensitivity, marginally higher than the clinician-collected sensitivity of 92.1% for the same endpoint.
- Specificity for pad-derived samples was lower than clinician sampling, but negative predictive value (the chance a negative result truly indicates absence of disease) was identical for both methods.
- Referral rates for further diagnostic work-up were comparable between pad-collected and clinician samples, indicating similar downstream burdens on services.
- Study authors and commentators framed the test as a standardised, non-invasive option; the work was published in BMJ and described as large-scale and community-based by the investigators.
- Experts cautioned results are preliminary: broader, more diverse trials are needed before replacing established screening pathways.
Background
Routine cervical screening commonly relies on clinician-taken cervical samples obtained with a brush or swab inserted into the vagina during a healthcare visit. That method is effective but participation gaps persist: millions invited to screening do not attend, often due to discomfort, logistical barriers, or cultural reasons. Human papillomavirus (HPV) infection is the primary cause of cervical cancer and detecting high-risk HPV is core to modern screening programs, which increasingly accept self-sampling kits as an alternative.
Self-sampling methods to date have largely relied on vaginal swabs or urine tests; menstrual blood is a less-tested matrix that is attractive because it is non-invasive and can be collected during a routine activity. Prior smaller studies suggested menstrual blood might contain diagnostically useful HPV DNA, but large, head-to-head comparisons with clinician-taken samples were lacking until this BMJ-published investigation. Any new method must be validated across age groups, menstrual patterns, and diverse ethnic and clinical settings before policy change.
Main Event
The Chinese team enrolled 3,068 participants aged 20 to 54 who reported regular menstrual cycles and asked each woman to provide three specimens: a menstrual-pad blood specimen captured on a strip affixed to a sanitary pad, a clinician-collected cervical sample, and an extra sample collected by a health worker for central laboratory processing. Laboratory assays targeted high-risk HPV types and assessed histological endpoints of cervical intraepithelial neoplasia grade 2 and grade 3 (CIN2 and CIN3), established precancerous changes that can require treatment.
When comparing diagnostic performance, the pad-collected samples showed a sensitivity of 94.7% for CIN2 detection, slightly higher than the 92.1% sensitivity observed for clinician-taken samples. Specificity was lower for pad samples, meaning more false positives occurred, but the negative predictive value — the probability that a negative test truly indicates absence of disease — was effectively identical for both approaches. Referral rates for follow-up investigations were reported as comparable.
Study authors concluded that minipad-collected menstrual blood could be used as a standardised, non-invasive alternative or replacement for clinician-collected cervical screening in appropriate populations. The paper, published in BMJ, notes the community-based design and relatively large sample size as strengths but acknowledges limitations that require further work before integration into national screening programs.
Analysis & Implications
If replicated in broader populations, menstrual-pad HPV testing could lower barriers to screening by offering a home-based, non-invasive option that many people find more acceptable than pelvic exams. Higher or comparable sensitivity for CIN2 suggests the method could identify most clinically significant precancers, which is the primary public-health objective of screening programs. However, lower specificity means more people without disease could be referred for unnecessary follow-up, with attendant costs and anxiety, so program planners must weigh trade-offs.
Integration into existing pathways would require validated laboratory workflows for a menstrual matrix, clear instructions for collection and transport, regulatory approvals, and quality assurance comparable to clinician sampling. Equity considerations are critical: the method is not applicable to people without menstruation, including many postmenopausal individuals, some trans and non-binary people on certain hormone therapies, and those with amenorrhea, so alternative options must remain available.
From a systems perspective, introducing menstrual-pad testing at scale could shift workloads from clinic spaces to laboratories and postal services, requiring investment in sample tracking and result management. Cost-effectiveness will depend on test price, rates of non-attendance currently, and how well a new option improves uptake among populations missing screening. Policymakers should require diverse, multicentre trials and implementation pilots before revising national guidelines.
Comparison & Data
| Sample type | Sensitivity for CIN2 | Specificity (relative) |
|---|---|---|
| Menstrual-pad blood | 94.7% | Lower than clinician samples |
| Clinician-collected cervical sample | 92.1% | Higher than pad samples |
The table summarises the headline performance figures; while sensitivity favoured the pad in this cohort, specificity did not. The study emphasises identical negative predictive values and similar referral rates, which are important for estimating real-world diagnostic pathways and service demand. These metrics must be re-evaluated in different populations and with longer follow-up to establish clinical endpoints such as cancer prevention and overtreatment rates.
Reactions & Quotes
Cancer Research UK welcomed exploration of new sampling methods but urged caution: further diverse trials are needed. The comment underscores the gap between promising diagnostic accuracy in controlled studies and safe, equitable roll-out.
Testing menstrual blood for HPV is an interesting, non-invasive approach and could potentially offer another option in the future.
Sophie Brooks, Cancer Research UK (health information manager)
An independent expert described the research as pioneering but still investigational, highlighting that clinical applications remain to be defined and regulated. This frames the finding as scientifically notable rather than immediately practice-changing.
The work is very pioneering, but at the moment its clinical applications are unclear.
Xavier Bosch, Emeritus researcher, Catalan Institute of Oncology
A charity for gynaecological cancers noted the potential acceptability gains but reminded readers the method would not suit everyone and that offering choices could improve participation. This reaction balances optimism with practical limits on eligibility.
It’s exciting to see more acceptable and potentially gentler ways of offering what could be a life-saving test, though it won’t work for everyone.
Athena Lamnisos, Chief Executive, Eve Appeal
Unconfirmed
- Whether menstrual-pad HPV testing performs equally well across different ethnic groups, age ranges beyond 20–54, and people with irregular cycles remains unverified.
- Long-term outcomes such as the method’s impact on cancer incidence, overdiagnosis, and overtreatment have not been established by this single study.
- The feasibility, cost implications, and logistics of national implementation (postal return, lab throughput, quality control) are untested at scale.
Bottom Line
The BMJ study of 3,068 women shows menstrual-pad blood testing can detect high-risk HPV and identify CIN2 with sensitivity comparable to clinician-collected samples, offering a promising non-invasive alternative for those who menstruate. Identical negative predictive values and similar referral rates strengthen the argument that pad sampling could be clinically meaningful in screening strategies, especially to reach people who currently avoid clinic-based tests.
However, the method is not yet ready to supplant established screening pathways. Regulators, clinicians, and public-health bodies should insist on multicentre trials in more diverse populations, operational pilots to assess logistics and costs, and clear guidance to ensure equitable access to other validated options for non-menstruating individuals. If subsequent research confirms these early results, menstrual-pad testing could become a valuable additional choice in cervical cancer prevention programs.